Patent · US Active

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

US12186278B2 · kind B2 · utility

0Cited by

44References

27Claims

0Family size

Assignees

Novartis AG · CH
The Trustees of the University of Pennsylvania · US
DANA-FARBER CANCER INSTITUTE, INC. · US
President and Fellows of Harvard College · US

Inventors

Jennifer Brogdon · Cambridge, US
Hwai Wen Chang · San Marcos, US
Boris Engels · Arlington, US
Gordon J. Freeman · Brookline, US
Gerhard Frey · San Diego, US
Jennifer Marie Mataraza · Cambridge, US
Reshma Singh · Cambridge, US
Arlene H. Sharpe · Brookline, US

Key dates

Filing date	Jul 11, 2022
Grant date	Jan 7, 2025
Priority date	—
Expiry date	Jun 29, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/38
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.